hrp0095rfc7.2 | Growth and Syndromes | ESPE2022
Miller Bradley
, Blair Joanne
, Højby Michael
, Böttcher Volker
, Juul Kildemoes Rasmus
, Maniatis Aristides
, Beck Bang Rikke
, Mori Jun
, Polak Michel
, Stagi Stefano
, Horikawa Reiko
Background: Growth hormone (GH) replacement therapy usually requires daily subcutaneous (s.c.) injections that can be burdensome for patients and their caregivers. Long-acting GH formulations aim to establish a less burdensome dosing regimen that is as safe and efficacious as daily GH to potentially improve adherence and clinical outcomes. Somapacitan, a long-acting reversible albumin-binding GH derivative, is in development for once-weekly s.c. administration...